Soligenix and Intrexon collaborate on melioidosis therapy development

Soligenix, Inc., recently announced on a new collaboration with Intrexon to develop a treatment for Melioidosis together, which will protect people from both a deadly disease and a biological weapon.

Soligenix, Inc., is a biopharmaceutical company which develops products to treat inflammatory diseases and ways to protect against biological threats without a current medical solution. Intrexon is a synthetic biological company which has proprietary technology to alter processes on the cellular level.

The new project seeks to develop a human monoclonal antibody therapy for biodefense and infectious disease threats for Melioidosis using Intrexon's proprietary technology. Intrexon has the ability to discover human antibodies, isolate them and reproduce them.

Melioidosis is a disease endemic to Southeast Asia and Northern Australia and is often lethal. It is considered a biodefense threat because of its potential to be used as a weapon through aerosol attacks. President and CEO of Soligenix Dr. Christopher J. Schaber said the planned therapy will be unique, since it will help treat the infected and protect against a biological threat.

"Our collaboration with Intrexon is consistent with our corporate strategy of building shareholder value through continuous evaluation of new product opportunities and acting upon those that meet Soligenix's mission of delivering disease-modifying therapies in areas of high unmet medical need," Schaber said. "By working with Intrexon we hope to make a potentially life-saving therapy available to patients in endemic regions and include the therapy in the national stockpiling program in case of a biowarfare event. Intrexon has a very strong track record of adding value both as a collaborator and a committed shareholder. We are very excited to join the exclusive coterie of Intrexon partner companies."